{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "TMDX",
  "name": "TransMedics Group, Inc.",
  "url": "https://frontierpicks.com/dossiers/TMDX/",
  "json_url": "https://frontierpicks.com/dossiers/TMDX.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "view_source": "research",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "TransMedics Group is modestly more likely to beat the S&P 500 over three months after third-quarter revenue grew 41% and the 2026 outlook was raised on 5 November 2026. The fourth-quarter report, expected in late February 2027, shows whether operating margins follow the volume growth.",
  "invalidation_trigger": "A daily close below $86, under the 200-day average, which would show the post-report re-rating fading. Also: 2026 revenue below the $764 million low end of the raised outlook.",
  "kill_line_kind": "price_line",
  "kill_line_due": null,
  "catalyst_date": "2026-12-01",
  "catalyst_estimated": false,
  "portfolio": null,
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "caveats": [
    {
      "claim": "TransMedics carries 1.50% convertible senior notes due 2028, with a net carrying value of $455.0 million at 2026-09-30.",
      "source": "Third-quarter 2026 results release, 8-K exhibit 99.1, 2026-11-05",
      "as_of": "2026-11-05"
    },
    {
      "claim": "The aircraft fleet is financed largely through finance leases, with $351.5 million of non-current finance-lease liabilities at 2026-09-30.",
      "source": "Third-quarter 2026 results release, 8-K exhibit 99.1, 2026-11-05",
      "as_of": "2026-11-05"
    }
  ],
  "source_links": [
    {
      "title": "TransMedics Group, Inc. - Form 8-K - FY2026",
      "url": "https://www.sec.gov/Archives/edgar/data/0001756262/000119312526449729/tmdx-ex99_1.htm",
      "date": "2026-11-05"
    },
    {
      "title": "Finviz",
      "url": "https://finviz.com/news/418067/transmedics-reaccelerates-to-41-growth-and-crushes-estimates-but-flat-margins-and-slipping-catalysts-keep-the-debate-open",
      "date": "2026-11-05"
    },
    {
      "title": "TransMedics to Present at Upcoming Investor Conferences",
      "url": "https://www.morningstar.com/news/pr-newswire/20261029ne85188/transmedics-to-present-at-upcoming-investor-conferences",
      "date": "2026-10-29"
    },
    {
      "title": "TransMedics Group Inc (TMDX) (Q3 2026) Earnings Call Highlights: Record $203 Million Revenue and Raised Full-Year Guidance",
      "url": "https://www.gurufocus.com/news/9180421/transmedics-group-inc-tmdx-q3-2026-earnings-call-highlights-record-203-million-revenue-and-raised-fullyear-guidance",
      "date": null
    }
  ],
  "evidence": [
    {
      "claim": "Third-quarter 2026 revenue was $203.0 million, up 41% from a year earlier (35% organic). Product revenue was $113.4 million, up 29%, and service revenue $89.6 million, up 60%.",
      "source": "Third-quarter 2026 results release, 8-K exhibit 99.1",
      "as_of": "2026-11-05"
    },
    {
      "claim": "The 2026 revenue outlook excluding PAD Aviation rose to $750–760 million from $737–757 million. Including about $14 million from PAD Aviation, it is $764–774 million.",
      "source": "Third-quarter 2026 results release, 8-K exhibit 99.1",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Third-quarter operating income was $28.1 million, a 13.9% margin, against $23.3 million and 16.2% a year earlier. Net income was $17.1 million, or $0.46 a diluted share.",
      "source": "Third-quarter 2026 results release, 8-K exhibit 99.1",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Trial-related revenue moved from late in the fourth quarter of 2026 into the first quarter of 2027. The CHOPS 510(k) filing moved to the second half of 2027.",
      "source": "Earnings Whispers summary of the 2026-11-05 earnings call",
      "as_of": "2026-11-05"
    },
    {
      "claim": "Free cash flow over the four quarters to 2026-09-30 was $45 million, from $112 million of operating cash flow after $68 million of capital spending.",
      "source": "Form 10-Q for the third quarter of 2026",
      "as_of": "2026-11-05"
    },
    {
      "claim": "UBS raised its TransMedics price target to $88 from $77 and kept a Neutral rating.",
      "source": "UBS, reported 2026-11-09",
      "as_of": "2026-11-09"
    },
    {
      "claim": "Director James Tobin sold 4,059 shares on the open market on 2026-11-09 at an average price of $94.97.",
      "source": "SEC Form 4 filed 2026-11-12",
      "as_of": "2026-11-12"
    },
    {
      "claim": "Director David Weill bought 1,336 shares on the open market on 2026-09-11 at $81.63.",
      "source": "SEC Form 4 filed 2026-09-14",
      "as_of": "2026-09-14"
    }
  ],
  "view_changes": [],
  "frame": {
    "as_of": "2026-11-20",
    "business": "TransMedics sells its Organ Care System, which keeps donor hearts, lungs and livers functioning outside the body, to US transplant centers. It also earns service revenue from organ retrieval and its own aircraft fleet. Revenue was $203 million in the quarter to 2026-09-30 (10-Q filed 2026-11-05).",
    "change": {
      "now": "On 2026-11-05 TransMedics reported third-quarter revenue of $203.0 million, up 41%. It raised its 2026 outlook to $764–774 million, including about $14 million from PAD Aviation (8-K).",
      "next": "Operating expenses rose to $90.5 million from $61.3 million, and research spending nearly doubled. Operating margin fell to 13.9% from 16.2%, and PAD Aviation's charter work cut gross margin to 58.5%.",
      "linked": "The 22 Embraer (ERJ) Phenom 300E jets get Gogo (GOGO) inflight connectivity under a deal announced 2026-10-27. US transplant centers will see trial revenue and the CHOPS 510(k) filing slip into 2027."
    },
    "priced_in": "At the 2026-11-19 close (filed inputs to 2026-11-05) the shares trade at 22.6 times earnings and 5.9 times book, with a 1.4% free-cash-flow yield; enterprise value is not available. Those multiples hold only if revenue keeps growing near the 41% of the latest filed quarter and the 13.9% operating margin widens, since four-quarter free cash flow was only $45 million.",
    "priced_in_filed": null,
    "links": {
      "customers": [],
      "suppliers": [
        {
          "ticker": "ERJ",
          "url": null
        },
        {
          "ticker": "GOGO",
          "url": "https://frontierpicks.com/dossiers/GOGO/"
        }
      ],
      "competitors": []
    }
  },
  "filed_numbers": {
    "as_of": "2026-11-20",
    "sector": "Healthcare",
    "financials": {
      "status": "ok",
      "reason": null,
      "close_date": "2026-11-20",
      "latest_quarter": "2026-09-30",
      "figures": {
        "revenue": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "value_musd": 203,
              "yoy_pct": 41.1
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-04",
              "restated": null,
              "value_musd": 189.9,
              "yoy_pct": 20.7
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-05",
              "restated": null,
              "value_musd": 173.9,
              "yoy_pct": 21.2
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-24",
              "restated": null,
              "value_musd": 160.8,
              "yoy_pct": 32.2
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-29",
              "restated": null,
              "value_musd": 143.8,
              "yoy_pct": 32.2
            },
            {
              "end": "2025-06-30",
              "filed": "2025-07-30",
              "restated": null,
              "value_musd": 157.4,
              "yoy_pct": 37.7
            }
          ]
        },
        "gross_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "pct": 58.5
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-04",
              "restated": null,
              "pct": 59.6
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-05",
              "restated": null,
              "pct": 58.2
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-24",
              "restated": null,
              "pct": 58.1
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-29",
              "restated": null,
              "pct": 58.8
            },
            {
              "end": "2025-06-30",
              "filed": "2025-07-30",
              "restated": null,
              "pct": 61.4
            }
          ]
        },
        "operating_margin": {
          "status": "ok",
          "quarters": [
            {
              "end": "2026-09-30",
              "filed": "2026-11-05",
              "restated": null,
              "pct": 13.9
            },
            {
              "end": "2026-06-30",
              "filed": "2026-08-04",
              "restated": null,
              "pct": 12.5
            },
            {
              "end": "2026-03-31",
              "filed": "2026-05-05",
              "restated": null,
              "pct": 7.6
            },
            {
              "end": "2025-12-31",
              "filed": "2026-02-24",
              "restated": null,
              "pct": 13.2
            },
            {
              "end": "2025-09-30",
              "filed": "2025-10-29",
              "restated": null,
              "pct": 16.2
            },
            {
              "end": "2025-06-30",
              "filed": "2025-07-30",
              "restated": null,
              "pct": 23.2
            }
          ]
        },
        "pretax_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 24.1
        },
        "net_income": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "four_quarters_end": "2026-09-30",
          "value_musd": 17.1,
          "four_quarters_musd": 144.5
        },
        "operating_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": 112.4
        },
        "capital_spending": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": 67.7
        },
        "free_cash_flow": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "first_end": "2025-12-31",
          "value_musd": 44.7
        },
        "diluted_share_change": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "base_end": "2025-09-30",
          "pct": 0.2
        },
        "cash": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 511.4
        },
        "debt": {
          "status": "not available"
        },
        "net_cash": {
          "status": "not available"
        },
        "deferred_revenue": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 1.5,
          "yoy_pct": -54.7
        },
        "backlog": {
          "status": "not reported"
        },
        "receivables": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 114.9
        },
        "inventory": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 58.4
        },
        "equity": {
          "status": "ok",
          "end": "2026-09-30",
          "filed": "2026-11-05",
          "value_musd": 550.7
        },
        "market_value": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-11-02",
          "basis_filed": "2026-11-05",
          "value_musd": 2961.1
        },
        "enterprise_value": {
          "status": "not available"
        },
        "ev_sales": {
          "status": "not available"
        },
        "ev_ebit": {
          "status": "not available"
        },
        "pe": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-11-02",
          "basis_filed": "2026-11-05",
          "multiple": 20.5
        },
        "pb": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-11-02",
          "basis_filed": "2026-11-05",
          "multiple": 5.4
        },
        "fcf_yield": {
          "status": "ok",
          "close_date": "2026-11-20",
          "basis_end": "2026-11-02",
          "basis_filed": "2026-11-05",
          "pct": 1.5
        }
      }
    },
    "short_interest": {
      "status": "ok",
      "settlement": "2026-10-30",
      "published": "2026-11-10",
      "short_pct_of_outstanding": 25.56,
      "days_to_cover": 10.2,
      "change_pct": 1.2
    },
    "insiders": {
      "status": "not available yet",
      "as_of": null,
      "windows": []
    }
  },
  "body_markdown": "## Current Thesis\n\nTransMedics Group is modestly more likely than not to beat the S&P 500 over the next three months. Revenue growth sped up to 41% in the third quarter, the company raised its 2026 outlook on 2026-11-05, and the shares are back above their 200-day average. The Piper Sandler conference appearance on 2026-12-01 and the fourth-quarter report, expected in late February 2027, will show whether profit margins keep up with case volume.\n\nThe rating is Medium, about a 55% chance of leading the index. The business case improved on 2026-11-05: third-quarter revenue was $203.0 million, up 41% from a year earlier (35% organic), and the 2026 revenue outlook rose to $764–774 million, according to the company's 8-K. Two things hold the rating below High. Several milestones slipped into 2027. The operating margin, at 13.9%, is still below the 16.2% of a year earlier.\n\n## Bull Case\n\n- **Revenue growth sped up in the third quarter.** Third-quarter revenue of $203.0 million grew 41% from a year earlier, after 20.7% in the second quarter (10-Q filed 2026-11-05). Service revenue rose 60% to $89.6 million and product revenue rose 29% to $113.4 million (8-K, 2026-11-05).\n- **The 2026 revenue outlook went up.** Excluding PAD Aviation, the 2026 range rose to $750–760 million from $737–757 million. Including about $14 million from PAD Aviation, it is $764–774 million (8-K, 2026-11-05).\n- **Adjusted margin has risen three quarters running.** Adjusted operating margin was 14.2% in the third quarter, up from 13.6% in the second and 10.4% in the first, according to Earnings Whispers' summary of the 2026-11-05 call. Product gross margin reached 79.2%.\n- **The company is profitable and holds cash.** Net income was $17.1 million, or $0.46 a diluted share, in the third quarter (8-K, 2026-11-05). Cash and short-term investments were $511 million at 2026-09-30 (10-Q).\n- **New programs reach further into 2027.** The FDA approved trial plans for ENHANCE Heart Part B and DENOVO Lung in October 2026. The company won its first European transplant logistics tender, in Italy, that same month (8-K, 2026-11-05).\n\n## Bear Case\n\n- **Several milestones moved into 2027.** Trial-related revenue moved from late in the fourth quarter of 2026 into the first quarter of 2027. The CHOPS 510(k) filing moved from the first half to the second half of 2027, according to Earnings Whispers' 2026-11-05 call summary.\n- **Margins are still below last year.** Operating margin was 13.9% in the third quarter, against 16.2% a year earlier and 23.2% in the quarter to 2025-06-30 (10-Q filings). Operating expenses rose to $90.5 million from $61.3 million, and research spending nearly doubled to $29.2 million (Earnings Whispers, 2026-11-05).\n- **Aviation lowers the blended margin.** PAD Aviation's charter business cut gross margin to 58.5%, from 61.1% without it. Service gross margin fell to 32.2%, and management guided to further normalization in the fourth quarter (Earnings Whispers, 2026-11-05).\n- **Free cash flow is thin and the balance sheet carries debt.** Free cash flow was $45 million over the four quarters to 2026-09-30, after $68 million of capital spending (10-Q). The 8-K lists $455.0 million of convertible notes due 2028 and $351.5 million of finance-lease liabilities.\n- **No 2027 targets and an insider sale.** Management gave no 2027 margin guidance and did not repeat its earlier target of a 30% operating margin by 2028 (Earnings Whispers, 2026-11-05). Director James Tobin sold 4,059 shares on 2026-11-09 at an average of $94.97 (SEC Form 4, filed 2026-11-12).\n\n## Setup & Price Structure\n\nThe shares closed at $94.02 on 2026-11-19. That is above both the 50-day average of $80.82 and the 200-day average of $90.84. The 3-month change is −0.8%, measured from the 2026-08-21 close of $94.77. The most recent closes held between $91.38 (2026-11-13) and $96.43 (2026-11-18).\n\nMost of the recovery came in one session. On 2026-11-06, the day after the report, the shares rose about 28%, according to Earnings Whispers' coverage. A common market view is that stocks keep drifting the way a large earnings-day jump points. Tests across US stocks have found no reliable effect so far.\n\nThe longer range is wide. The 52-week intraday high was $156.00 on 2025-12-02, and the last close is 39.7% below it. The 52-week closing low was $62.04 on 2026-05-14. The 200-day average is the nearest level the case turns on. A sustained move back under it would show the market giving back the re-rating that followed the report.\n\nUBS raised its target to $88 from $77 on 2026-11-09 and kept a Neutral rating. Director David Weill bought 1,336 shares at $81.63 on 2026-09-11 (SEC Form 4).\n\n## Catalyst Calendar\n\n- **2026-12-01:** TransMedics presents at the Piper Sandler 38th Annual Healthcare Conference in New York. It is the first management update after the report. Comments on fourth-quarter case volume, aviation activity after a soft October, and 2027 margins would test the outlook raised on 2026-11-05.\n- **~2027-01-11 (est.):** J.P. Morgan Healthcare Conference, where the company has presented in past years. Any early read on 2026 revenue or 2027 targets would show whether the raised outlook was met.\n- **~2027-02-25 (est.):** Fourth-quarter and full-year 2026 results. These settle whether 2026 revenue lands within $764–774 million and whether the company sets 2027 revenue and margin goals.\n\n## What Would Change Our Mind\n\nA daily close below $86, under the 200-day average, which would show the post-report re-rating fading. Also: 2026 revenue below the $764 million low end of the raised outlook.\n\nThe risks this note tracks, each with what would confirm it:\n\n- Aviation and service costs keep the operating margin from widening as volume grows. Confirmed by: A fourth-quarter adjusted operating margin below the third quarter's 14.2%, or service gross margin below 32.2%, at the next report.\n- Weaker US donor supply slows liver and heart case growth. Confirmed by: Management reporting falling case volume from the previous quarter, or 2026 revenue below $764 million, at the fourth-quarter report.\n- Clinical and regulatory milestones slip further, pushing new-program revenue beyond 2027. Confirmed by: The company moving the CHOPS 510(k) filing past the second half of 2027, or trial revenue past the first quarter of 2027.\n- The 2027 outlook resets growth expectations lower after the 41% third quarter. Confirmed by: A 2027 revenue outlook implying growth below the 24%–26% organic growth guided for 2026.\n- Debt and lease costs absorb cash as the fleet grows. Confirmed by: Four-quarter free cash flow falling below the $45 million reported to 2026-09-30, or new borrowing against the 2028 convertible notes.\n\n## Correlation Notes\n\nThe shares trade mostly on company-specific news: quarterly reports, trial approvals and aviation economics. Medtech peers move them little. A 52-week range running from a $156.00 intraday high to a $62.04 closing low shows how large those swings have been. For scale, the standard deviation of 63-session returns across liquid US stocks was 27% in 2026. That figure describes the market as a whole.\n\nTransplant volume depends on donor supply. Management said on the 2026-11-05 call that US deceased donors fell 6%. It said it sees no obstacle to the business in the new CMS (Centers for Medicare & Medicaid Services) rule for organ procurement organizations. The aviation side links the company to Embraer (ERJ), which built the 22 Phenom 300E jets in its fleet, and to Gogo (GOGO), chosen on 2026-10-27 to supply their inflight connectivity. Neither link moves the case for the shares.",
  "first_seen": "2026-11-20",
  "last_analyzed": "2026-11-20T07:09:50+00:00",
  "last_synthesized": "2026-11-20",
  "date_modified": "2026-11-20",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}